Is Casi Pharmaceuticals Inc (NASDAQ:CASI) a Buy? The Stock Reported Less Sellers

June 25, 2018 - By Kenneth Lin

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Logo

Investors sentiment increased to 2 in 2018 Q1. Its up 0.10, from 1.9 in 2017Q4. It increased, as 1 investors sold CASI Pharmaceuticals, Inc. shares while 10 reduced holdings. 10 funds opened positions while 12 raised stakes. 4.96 million shares or 39.41% more from 3.56 million shares in 2017Q4 were reported.
Perceptive Advsr Limited Liability Com holds 43,682 shares or 0.01% of its portfolio. Verition Fund Mgmt Lc reported 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Susquehanna Gru Llp accumulated 140,680 shares or 0% of the stock. Moreover, Geode Cap Management Limited Co has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Fincl Bank Of Mellon Corp holds 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 36,880 shares. Moreover, Goldman Sachs Grp has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Royal Bank Of Canada stated it has 17,545 shares. Millennium Mgmt reported 430,297 shares. Atlantic Gru Ltd Liability has 100 shares. Barclays Public Ltd holds 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 46,200 shares. Guggenheim Capital Lc reported 10,949 shares. Wells Fargo And Com Mn accumulated 60 shares. Financial Bank Of America De has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Penobscot Invest Mgmt Com holds 0.03% or 27,000 shares. Northern Corporation has 73,987 shares.

The stock of Casi Pharmaceuticals Inc (NASDAQ:CASI) registered a decrease of 7.88% in short interest. CASI’s total short interest was 1.72M shares in June as published by FINRA. Its down 7.88% from 1.87M shares, reported previously. With 671,400 shares average volume, it will take short sellers 3 days to cover their CASI’s short positions. The short interest to Casi Pharmaceuticals Inc’s float is 6.29%.

The stock increased 9.98% or $0.57 during the last trading session, reaching $6.28. About 6.30 million shares traded or 590.69% up from the average. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has risen 585.86% since June 25, 2017 and is uptrending. It has outperformed by 573.29% the S&P500.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $540.99 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

More important recent CASI Pharmaceuticals, Inc. (NASDAQ:CASI) news were published by: which released: “Mid-Morning Market Update: Markets Open Lower; Kroger Earnings Beat Expectations” on June 21, 2018, also published article titled: “44 Stocks Moving In Thursday’s Mid-Day Session”, published: “Here’s Why CASI Pharmaceuticals Rose as Much as 31.6% Today” on June 21, 2018. More interesting news about CASI Pharmaceuticals, Inc. (NASDAQ:CASI) was released by: and their article: “Mid-Day Market Update: Dow Down Over 150 Points; CASI Pharmaceuticals Shares Spike Higher” with publication date: June 21, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: